SCHEMBL20536506

SCHEMBL20536506

COC(=O)/C(=C\c1ccccc1Oc1ccccc1Cl)N=[N+]=[N-]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.37
▸ PLA2G1B P04054 1/20 0.37
▸ ATG4B Q9Y4P1 1/20 0.37
▸ HDAC1 Q13547 1/20 0.37
▸ HDAC8 Q9BY41 1/20 0.37
▸ HDAC6 Q9UBN7 1/20 0.37
▸ CXCL8 P10145 1/20 0.36
▸ MEN1 O00255 3/20 0.34
▸ KMT2A Q03164 3/20 0.34
▸ PLIN1 O60240 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ PLIN5 Q00G26 1/20 0.34
▸ ABHD5 Q8WTS1 1/20 0.34
▸ XIAP P98170 1/20 0.34
▸ HPGD P15428 2/20 0.33
▸ CAMK2A Q9UQM7 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ HSP90AA1 P07900 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19343560 0.87 MAPT (0.40) MAPTHDAC1HDAC8HDAC6MEN1
SCHEMBL23709923 0.86 HTT (0.48) MAPTPLA2G1BATG4BMEN1KMT2A
SCHEMBL29015396 0.85 HTT (0.45) MAPTMEN1KMT2APLIN1LMNA
SCHEMBL14337628 0.85 MAPT (0.48) MAPTMEN1KMT2APLIN1LMNA
SCHEMBL23709928 0.83 LMNA (0.51) MAPTMEN1KMT2ALMNAADORA2A
SCHEMBL19342168 0.83 ALDH1A1 (0.41) MAPTHDAC1MEN1KMT2ALMNA
SCHEMBL23709914 0.82 LMNA (0.47) MAPTMEN1KMT2APLIN1LMNA
SCHEMBL23709904 0.81 RHEB (0.35) MAPTPLA2G1BATG4BMEN1KMT2A
SCHEMBL19330972 0.81 ADORA2A (0.41) MAPTMEN1KMT2APLIN1LMNA
SCHEMBL19343377 0.81 ADORA2A (0.41) MAPTMEN1KMT2APLIN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 — — US disclosed
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 — — US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 — — US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 — — US disclosed
WO-2018191146-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2018-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF RHEB, KRAS, NRAS MAPT 4119/4885PLA2G1B 143/4885ATG4B 448/4885
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof RHEB, GDI2, KRAS MAPT 2840/4885PLA2G1B 385/4885ATG4B 1003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback